IOVA · Iovance Biotherapeutics Inc
United States · RS rating 89 · As of 2026-11-03
| Price | 8.83 USD |
|---|---|
| 1-day change | +10.1% |
| RS rating (overall / 1M / 3M / 12M) | 89 / 8 / 97 / 98 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 47 / 57 / 47 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +28.0% |
| Sales growth Q/Q | +28.6% |
| Distance from 52-week high | +40.6% |
| Market cap (USD) | $1.4B |